Prognosis of localized diffuse large b-cell lymphoma in younger patients: Predictive value of age- and stage-adjustment of the International Prognostic Index

The International Prognostic Index (IPI) is widely used as a predictive model in diffuse large B-cell lymphoma (DLBCL) patients of all ages and stages. To determine the optimal IPI-based prognostic system at the time of diagnosis in younger patients with limited-stage DLBCL, the authors evaluated th...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2003-08, Vol.98 (3), p.516-521
Main Authors: MØLLER, Michael B, CHRISTENSEN, Bjarne E, PEDERSEN, Niels T
Format: Article
Language:English
Subjects:
Biological and medical sciences
Hematologic and hematopoietic diseases
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Medical sciences
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The International Prognostic Index (IPI) is widely used as a predictive model in diffuse large B-cell lymphoma (DLBCL) patients of all ages and stages. To determine the optimal IPI-based prognostic system at the time of diagnosis in younger patients with limited-stage DLBCL, the authors evaluated the age- adjusted IPI and the recently proposed stage-adjusted IPI, and constructed an IPI-based model adjusted for both age and stage. From the population-based LYFO registry of the Danish Lymphoma Group, 233 patients not older than 60 years with Stage I-II DLBCL treated with anthracycline-based chemotherapy with or without involved-field irradiation were identified. The primary endpoint of analysis was overall survival. At the end of the observation period, 151 patients were alive with a median follow-up time of 8.3 years. All the variables in the age-adjusted and the stage-adjusted IPI had major prognostic significance (P
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.11497